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1. Introduction 
 
1.1. Glycosylation and lectins 
The glycosylation of proteins and lipids is a common posttranslational modification 
that regulates many physiological processes, like cell to extracellular matrix, cell to cell 
adhesion, assembly and activation of receptor complexes and protein trafficking (1). The role 
of glycosylation in cell physiology becomes better understandable with the characterization of 
the lectins, proteins that have binding sites for the specific mono- di- or oligosaccharides 
linked to proteins or lipids (1). There are several types of lectins: 
1) The C-type lectins need calcium for recognition of their ligands and fulfill a variety 
of functions predominantly in the immune system. Selectins, for example, are C-type lectins 
known to mediate interaction between the blood and endothelial cells (1). 
2) The P-type lectins are mannose-6-phosphate receptors that participate in the 
trafficking of enzymes to prelysosomal compartments (2, 3). 
3) The I-type lectins or siglecs are carbohydrate-binding proteins belonging to the 
immunoglobulin superfamily (4). One of them is CD22, which is expressed on mature B-cells 
and mediates interactions with glycoproteins expressed on B- or T-cells. 
4) The galectins are described below in details. 
5) The L-type lectins are involved in protein sorting in luminal compartments of 
animal cells (5). 
6) The M-type lectins are a recently described family of intracellular lectins involved 
in glycoprotein trafficking (6, 7). They resemble mannosidases found in the endoplasmic 
reticulum (ER), but they lack the key catalytic residues. 
7) The R-type lectins contain ricin-like carbohydrate recognition domains (CRD) (8). 
These lectins are involved in enzyme targeting and glycoprotein hormone turnover. 
8) Calnexin and calreticulin are parts of the quality control system for glycoproteins in 
the ER (9) They bind to the terminal glucose residues on N-linked oligosaccharides and retain 
misfolded glycoproteins in the ER. 
Table 1.1 is a brief summary of existing lectin families, their ligands, and function. 
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Lectin Group Typical Ligands Examples of functions 
   
   
C-type lectins 
 
Various 
 
Cell adhesion (Selectins). Glycoprotein clearance. 
Innate immunity (Collectins). 
P-type lectins Man 6-phosphate Post Golgi protein sorting. 
I-type lectins Sialic acid Cell adhesion (Siglecs). 
Galectins β-Galactosides Various. Discussed below in details. 
L-type lectins Various Protein sorting in the endoplasmic reticulum 
M-type lectins 
 
Man8 
 
ER-associated degradation 
of glycoproteins. 
R-type lectins Various Enzyme targeting, glycoprotein hormone turnover. 
Calnexin and 
Calreticulin 
Glc1Man9 
 
Protein sorting in the endoplasmic reticulum. 
 
 
Table 1.1. Types of animal lectins, their ligands and function. 
 
Many of the above mentioned lectins play an important role in the immune system. 
 
1.2. Lectins in the immune system 
The role of the lectins in the immune system may be subdivided into four separate 
categories, although they are not mutually exclusive: 
-direct defense (antibody- and/or complement-like); 
-recognition and trafficking within the immune system; 
-immune regulation (suppression or enhancement); 
-prevention of autoimmunity. 
I-type lectins play an important role mostly in the immunity of invertebrates, but are 
not only confined to them. In higher animals, including humans, there are collectins (10, 11), 
ficolins (10), and the membrane-bound macrophage mannose receptor (12, 13), all of which 
recognize and directly promote the elimination of pathogens. A few lectins like 32-kilodalton 
macrophage membrane protein from Candida albicans (14) or ovgal11 from sheep (15) are 
considered to resemble complement components more than immunoglobulins. 
The selectins function in cell trafficking, promoting extravasation via the ‘‘rolling’’ 
capture of leukocytes, as was shown in selectin knock out mice (16). Several other adhesion 
molecules with lectin activity have been implicated in cell trafficking: CD44 has a role in the 
lymphocyte recirculation (17), CD22 mediates the homing of murine B cells to the bone 
marrow (18), CD11b/CD18 mediates monocyte and neutrophil adhesion to the endothelium 
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and thus promotes extravasation of neutrophils to the sites of inflammation (19). CD31 also 
influences neutrophil migration in response to inflammatory stimuli (20). 
A number of cytokines, including IL-1, IL-2, IL-6, IL-12 and TNFα have lectin 
activity (21-23). The immunoregulatory properties of these cytokines are well known, and are 
mediated by protein–protein binding to their cytokine receptors. Much less is known about the 
role of lectin activity, but some indications of an immunoregulatory role are emerging. For 
example, there is some evidence that IL-2 can bind to a high mannosyl moiety on the IL-2Rα 
subunit to promote the formation of a high affinity complex of IL-2/ IL-2Rα/IL-2Rβ/IL-2Rγ 
subunits leading to cellular signaling (24). Other lectins that may be involved in modulating 
the immune response include sarcolectin, which has been implicated in growth regulation 
(25), and the I-type lectins. There are now 10 members of the latter group of adhesion 
molecules (26,), and while their function(s) has not been clearly defined, several are believed 
to have a signal within the immune system. The plant lectins, mistletoe lectins and wheat 
germ agglutinin (WGA), have been implicated in cancer therapy because of the modulation of 
an immune response (27, 28). One possible target for WGA is the CD45 receptor tyrosine 
phosphatase, since binding of WGA to CD45 results in the decrease of phosphatase activity 
(29). 
Members of the galectin family of animal lectins are important regulators of processes 
in immune system. 
 
1.3. Galectin lectin family 
The galectins are the beta-galactoside binding lectins with a carbohydrate recognition 
domain that has many conserved sequence elements. In addition to the galectins expressed in 
vertebrates (fish (30), birds (31), amphibians (32), and mammals (reviewed in ref. 33)), 
galectins have also been found in invertebrates (worms (34) and insects (35)) and even in 
protists (sponge (36) and fungus (37)). Utilizing the binding of the galectins to beta-
galactoside, it was possible to purify them by lactose affinity chromatography. After cloning 
and sequencing the first galectins novel galectin family members are now being rapidly 
discovered by screening for related sequences in the DNA data banks (38). For instance, 
while fourteen human galectin proteins are already characterized, another eight related genes 
have been identified in the human genome by sequence similarity (39). The CRD of the 
galectins folds as a globule of two antiparallel β-sheets formed by five and six beta strands 
(Fig. 1.1.) (39). 
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Fig.1.1. Crystal structure of galectin-1 dimer complexed with lactose (from Ref. 40). 
 
Although galectins are often reported to be present on the cell surface (41) or in the 
extracellular matrix (42), they lack recognizable secretion signal sequences and do not pass 
through the standard ER/Golgi pathway when secreted (43, 44), with the possible exceptions 
of a sponge galectin (36) and several other invertebrate galectins (38). Instead, most galectins 
have characteristics of cytoplasmic proteins, such as an acetylated N-terminus, free 
sulfhydryls, and lack of glycosylation. Indeed, intracellularly they appear to be cytosolic (45), 
submembranous (46), or sometimes nuclear (47), but not compartmentalized inside the 
classical secretory compartments. Nevertheless, there is strong experimental evidence that at 
least some galectins are secreted, albeit by novel nonclassical mechanisms (43, 44). In this 
regard, galectins belong to a small category of proteins (including FGF-1 and –2 (48)) that are 
secreted by mechanisms thar are distinct from the classical vesicle-mediated exocytosis (Fig. 
1.2). 
Fig.1.2. A possible mechanism of galectin secretion. Expressed protein accumulates near the cell 
membrane; when concentration of galectin near membrane becomes high it induces membrane 
blebbing and formation of a vesicle; disruption of a vesicle leads to galectin release (from Ref. 
49). 
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All galectins identified to date can be structurally classified into three basic types (Fig. 
1.3). 
The ‘‘prototype’’ galectins contain a single CRD. Most of these proteins are able to 
self-associate to form homodimers. Chicken galectins C-14 and C-16 (50) resemble 
mammalian galectin-1, but the former one occurs as a monomer, while the latter one forms 
homodimers. The prototype galectins dimerize through their N- and C-terminal regions as was 
shown by mutagenesis (51) and crystallographic studies (52). Thus, the CRD pockets and any 
bound ligands face away from each other. The ‘‘tandem-repeat’’ galectins are composed of 
two nonidentical core galectin domains joined either directly or via a linker peptide of 
variable length (53, 54, 55). Crystal structures have not yet been obtained for any tandem-
repeat class galectins. The only known member of the ‘‘chimeric’’ galectins, galectin-3, is 
composed of a galectin domain joined to a N-terminal non-lectin domain. The N-terminal 
domain of galectin-3 contains proline, glycine, and tyrosine rich repeats followed by a C-
terminal CRD. The repetitive domain is similar to the ones found in certain other proteins, 
such as synexin and synaptophysin, where it is proposed to function in self-aggregation (56). 
 
The presence of galectins in so many species including very ancient ones suggests that 
they evolved to play fundamental roles in cell biology, while the presence of multiple 
galectins within different species suggests that they have diverged to fulfill a variety of more 
specific functions. Mammalian galectins identified so far are presented in Table 1.2. 
 
Fig.1.3. Three structural types of galectins. The “prototype” galectins are composed of a single CRD;  
the “chimeric” galectin-3 has nonlectin domain fused to galectin CRD; the “tandem-repeat” galectins 
have two distinct CRDs linked together by a linker sequence. (taken from 
http://www.glycoforum.gr.jp/science/word/lectin/LEA01E.html ) 
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Galectin 
 
Type 
 
Localization 
 
Glycoconjugate ligands 
 
    
1 
 
 
 
 
Prototype 
(monomeric/dimeric) 
 
 
 
Most organs, lymph 
nodes, spleen, thymus, 
placenta, prostate, 
macrophages, B cells, T 
cells, tumors. 
Matrix glycoproteins: 
laminin and fibronectin, 
90K/Mac-2BP. Cell surface 
receptors: CD45, CD43, 
CD7, CD2, CD3 and GM1 
2 
 
Prototype 
(monomeric/dimeric) 
Gastrointestinal tract, 
tumors  
3 
 
 
 
Chimera-type 
 
 
 
Mainly in tumor cells, 
macrophages, epithelial 
cells, fibroblasts and 
activated T cells 
Matrix glycoproteins: 
laminin and fibronectin, 
LAMPS, 90K/Mac-2BP, 
MP20 and CEA. 
4 Tandem repeat-type Gastrointestinal tract  
5 Prototype Erythrocytes  
6 Tandem repeat-type Gastrointestinal tract 90K/Mac-2 BP 
7 
 
Prototype 
 
Skin and tumors of 
epidermal origin  
8 
 
 
Tandem repeat-type 
with novel prototype 
isoforms 
Liver, prostate, kidney, 
cardiac muscle, lung 
and brain  
9 
 
 
Tandem repeat-type 
 
 
Thymus, T cells, kidney 
and Hodgkin´s 
lymphoma  
10 
 
Prototype 
 
Eosinophils and 
basophils  
11 
 
Prototype and 
dimeric 
Lens 
  
12 Tandem repeat-type Adipocytes  
13 Prototype Placenta  
14 Prototype Eosinophils  
 
Table. 1.2. Galectin family of animal lectins, localization and glycoconjugate ligands. 
 
1.4. Properties and functions of galectin-1 
Galectin-1 was the first member of the galectin family to be described (57). It 
specifically recognizes beta-galactosides and has conserved sequence elements characteristic 
of galectins. The chain of 134 amino acids folds into the typical galectin CRD globule (Fig. 
1.1). Two identical galectin-1 globules can form a dimer (58). Dimerization involves self-
association of monomer subunits via hydrophobic surfaces opposite to the sugar-binding 
pocket (59). The hydrophobic surfaces are formed by the amino acidcs 4-7 of the N terminus 
and the amino acids 126, 128, and 131 of the C-terminus (Fig.1.4) Mutations of hydrophobic 
amino acids in these regions lead to the inability of galectin-1 to form dimers.(51). The 
dissociation constant (Kd) of the dimer is 7μM (60). Although galectin-1 has six cysteines 
(Fig.1.4), disulfide bonds are not formed in the native protein and they exist as free 
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sulfhydryls (40). Cysteine pairs 2 and 130, 16 and 88, 42 and 60 can form disulfide bonds in 
an oxidizing environment (61). Mutation of Cys2 makes the protein significantly more 
resistant to oxidation (62). Amino acids, which interact directly with sugar, were deduced 
from the crystal structure of galectin-1 (Fig.1.4.). A single mutation in any of the amino acids 
- His44, Asn46, Arg48, Asn61, Glu71, or Arg73 - abolishes binding to asialofetuin (63, 64). 
The amino acids are crucial in forming the pocket which binds Gal1-4GlcNAc via 4-OH and 
6-OH of galactose and 3(4)-OH of Glc (NAc) (63). It also shows high affinity for complex N-
glycans (63). Affinity increases with the number of branches up to triantennary N-glycans 
(63). The surface loop, comprising amino acid residues 25–30 (Fig.1.4), and joining two 
internal strands, forms part of the growth-inhibitory site, as was revealed by mutagenesis 
studies (65). 
 
 
Fig.1.4. Protein sequence of galectin-1. The cysteines are shown in bold and underlined. 
Amino acids crucial for sertain functions are shown by large letters and in bold. 4-7, 126, 128, 131 are 
important for dimer formation; 27,29 are parts of the growth inhibitory site; 44, 46 ,48, 68, 71, 73 are 
in direct contact with the sugar ligand. 
 
The activity of the galectin-1 gene is strongly modulated under a variety of 
physiological or pathological conditions. A small genomic region of no more than 100 base 
pairs surrounding the transcription start site (-50/+50), accounts for most of the transcriptional 
activity of the galectin-1 gene (66). Both upstream and downstream position-dependent cis-
elements are necessary for efficient transcriptional activity. Using the bisulfite genomic 
sequencing technique, it was found that the primary mechanism controlling the cell-specific 
expression and reactivation of the galectin-1 gene is the transition from a fully methylated to a 
fully unmethylated state of the 11 CpG sites lying around the transcription start site (67) 
Moreover, the in vitro methylated galectin-1 promoter is inactive when transfected into mouse 
fibroblasts. Also in normal mouse and rat tissues the rate of DNA methylation of the small 
CpG island surrounding the start site correlates with transcription activity (68). While in cell 
lines differences in DNA methylation are spread over a large area, in tissues differences in 
CpG modification are confined to the cluster of CpG surrounding the transcription start site. 
AC2GLVA4-7SNLN LKPGEC16LRVR GEVAPDA27KS29F VLNLGKDSNN 
LC42LH44FN46PR48FN AHGDANTIVC60 N68SKDGGAWGT E71QR73EAVFPFQ 
PGSVAEVC88IT FDQANLTVKL PDGYEFKFPN RLNLEAINYM 
AADGDF126KI128KC130 V131AFD 
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In this case, the methylation profiles in non-expressing tissues are highly heterogeneous and 
the density of methyl-CpGs rather than site-specific methylation, distinguishes the non-
expressing from the expressing alleles (68). 
The expression pattern of galectin-1 varies among different adult tissues, changes 
during development and is altered in many neoplastic transformations and other pathological 
conditions. The spatio-temporal distribution of the lectin in human and mouse embryogenesis 
has been thoroughly investigated (69). It is first expressed in the trophoectoderm cells of the 
implanting embryo and has been implicated in the process of implantation. In mouse embryos 
prominent expression of galectin-1 in the myotomes of the somites has been reported (69). In 
human embryogenesis, it is found prevalently in connective tissues and some epithelia, such 
as in the basal layers of the skin and in the epithelial cells of the gonads (70). In adult tissues, 
galectin–1 is abundantly expressed in many cell types, such as skeletal, smooth and cardiac 
muscle and other cells of mesenchymal origin. Galectin-1 might play an important role in 
skeletal muscle differentiation, since it was shown to be implicated in the conversion of 
dermal fibroblasts to muscle (71). High galectin-1 expression has been detected in sensory, 
motor and olfactory neurons and it has been demonstrated to participate in the regulation of 
olfactory axon fasciculation and targeting (72). In hematopoietic and lymphoid organs 
galectin-1 is expressed by stromal cells. In murine thymus, the lectin is expressed by thymic 
epithelial cells (73) and is detected throughout the stromal framework of the thymus. 
The expression patern of the galectin-1 gene in cell lines reproduces the one found in 
the tissues of origin. Galectin-1 is highly expressed in cells of mesenchymal origin and 
weakly or not expressed in epithelial cells. However, some conditions can dramatically 
modulate the expression of the lectin gene in cultured cells. The most important is the cellular 
transformation obtained by transfection of different oncogenes. Galectin-1 expression 
correlates with the degree of malignancy in rat thyroid cell lines transformed with several 
cellular or viral oncogenes (74). Its mRNA levels increase 20-fold in low tumorigenic and up 
to 100-fold in high tumorigenic cells. A transient increase in galectin-1 expression is also 
achieved upon treatment of thyroid cells with thyroid stimulating hormone (75). In human 
head and neck carcinoma cells lectin expression is stimulated by butyrate treatment (76). In 
this case, the expression correlates with growth inhibition and soft agar colony formation 
inhibition. Because galectin-1 expression is also increased upon treatment with other 
inhibitors of histone deacetylase, it has been proposed that expression is linked to the status of 
histone acetylation (77). In human endothelial cells, lectin synthesis is up-regulated by 
endothelial cell activation (77). Activation of the galectin-1 gene can also be achieved by 
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fusing non-expressing cells with tumor cells or by the treatment of non-expressing cells with a 
DNA demethylating agent (78). 
Galectin-1 expression is strongly affected in human tumors. Lectin mRNA levels are 
very low in normal thyroid non-neoplastic goiters, adenomas and follicular carcinomas, while 
they are increased (5-20-fold) in a large proportion of papillary carcinomas and in almost all 
the aggressive anaplastic carcinomas (74, 79). In immunohistochemical studies, however, a 
higher galectin-1 content relative to normal thyroid (20-30-fold) has been reported in all 
analyzed follicular and also in some medullary carcinomas (80). The data on galectin-1 
expression in tumors and its role in cancer cell adhesion has been the subject of a detailed 
analysis (81). 
Targeted disruption of the galectin-1 gene alone, or galectin-1 and galectin-3 genes 
together, was performed in mice. Galectin-1-/-, or galectin-1-/- together with galectin-3-/-, 
homozygous null mutants appear normal and fertile (82, 83). The potential role of galectin-1 
in the developing olfactory system was investigated in newborn mice. This analysis revealed 
that the absence of lectin results in major defects in primary olfactory neuron outgrowth (72). 
Because galectin-1 has been postulated to participate in regulating immune function (84), 
including T-lymphocyte selection in the thymus, complete blood counts were compared for 
control and galectin-1 “null” mutant mice. No significant differences were found in white cell 
numbers or differential distribution (85). However, potential differences in the prevalence of 
lymphocyte subtypes have not been investigated. 
Galectin-1 exhibits dual localization, both in the intracellular and extracellular 
compartments. Immunohistochemical studies demonstrated the presence of lectin in 
cytoplasm of smooth muscle (86) and thymic epithelial (73) cells, as well as in the nucleus of 
the same smooth muscle cells(86) and osteoblasts (87). Indirect immunofluorescence studies 
showed the presence of galectin-1 on the surface of K562 cells (41). The protein is also 
present in the extracellular environment in thymus(71) and bone marrow (88). In accordance 
with the dual localization, galectin-1 functions can be divided intracellularly and 
extracellularly. 
 
1.4.1. Extracellular function of galectin-1 
Extracellularly, galectin-1 participates in the regulation of cell activation, 
proliferation, adhesion and apoptosis. A topic of great interest is the regulation of these 
processes by galectin-1 in the immune system. 
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Modulation of adhesion by galectin-1 
Galectin-1 has been implicated in cell to cell and cell to extracellular matrix 
interactions. It may have anti- or pro-adhesive effect on the interaction. For large cell 
lymphoma the positive regulation of cell adhesion has been shown; the lectin was present on 
the surface of the endothelial cells and partially mediated the adhesion of RAW117-H10 large 
cell lymphoma cells to liver microvessel endothelial cells (89). The same positive effect was 
observed in human prostate carcinoma cell lines transfected with galectin-1 (90). The 
interaction of galectin-1 with the tumor secreted antigen, 90K has been shown to contribute to 
the formation of multicellular aggregates of human melanoma cells (91). It has also shown 
proadhesive effects toward other cell types such as olfactory neurons (92) For other cells, the 
negative regulation of cell adhesion was demonstrated. The lectin has been shown to inhibit 
myoblast interactions with laminin by blocking α7β1 integrin (93). It also inhibited A121 
ovarian carcinoma cell line adhesion to extracellular matrix (94). Presence of the lectin was 
shown to inhibit IL-2 activated T-cell adhesion to intact ECM, laminin and fibronectin, and to 
a lesser extent to collagen type IV, in a dose-dependent manner (95). This effect was 
specifically blocked by anti-galectin-1 antibody and was dependent on the lectin's 
carbohydrate-binding properties. Galectin-1 could promote cell attachment or detachment 
according to cell type, cell activation status, or cell developmental stage (reviewed in ref. 
(96)). Moreover, the binary actions of galectin-1 could also be associated to the high or low 
concentrations of galectin-1 in the extracellular milieu or the glycosylation state of the 
counter-receptors. 
 
Galectin-1 regulates cell growth 
Galectin-1 inhibits growth of different cell types: phytohemagglutinin (PHA)-
activated human T cells (95, 98), concanavalin A (Con A)-stimulated rat T cells (99), human 
neuroblastoma cells (100), human leukemia T cells (101), and murine fibroblasts (102). The 
growth inhibitory effect may depend on the carbohydrate-binding activity or be independent 
of the lectin-sugar interactions. A pioneer study conducted by Wells and Mallucci in 1991 
(102) showed that galectin-1 acts as an autocrine-negative growth factor and inhibits the 
growth of mouse embryonic fibroblasts in a carbohydrate-independent manner. Inhibition of 
proliferation of Con A-stimulated rat T cells was dose- and carbohydrate-dependent (99). 
Further investigation revealed that galectin-1 secreted by CD8+ T cells reduces clonal 
expansion of stimulated CD8+ T cells and interleukin (IL)-2 induced proliferation of PHA-
activated T lymphocytes in an autocrine manner by arresting the cells in the S and G2/M 
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phases of the cell cycle (97, 103). The negative regulation of cell growth by galectin-1 has 
been extended to some tumor cells. It was shown that cell density-dependent growth 
inhibition of human neuroblastoma cells is initiated by increased ganglioside sialidase 
activity, leading to increased cell-surface expression of the ganglioside GM1, which acts as a 
ligand for galectin-1 (100). 
It has been speculated that the growth inhibitory properties of this lectin are highly 
dependent on cell type, cell-activation status, and concomitant environmental signals. 
 
Galectin-1 induces apoptosis 
Galectin-1 induces apoptosis of T cells during their development in the thymus and 
after immune stimulation of the peripheral activated (104, 105, 84), but not resting (84, 106), 
T cells. The triggering of cell death does not occur via the T cell antigen receptor (TCR), Fas 
or tumor necrosis factor (TNF) receptor (84). As an early cell response, the lectin initiates 
tyrosine phosphorylation in T and B cell lines. Tyrosine kinase and phosphatase inhibitors, 
genistein and phenylarsine oxide or sodium vanadate, respectively, diminish the 
phosphorylation and the apoptotic effect, pointing out the role of the tyrosine phosphorylation 
events in the induction of apoptosis (R.Fajka-Boja, unpublished observations). Screening of a 
large panel of mAbs that would block galectin-1 binding to MOLT-4 human T cells revealed 
thatt Abs recognizing CD45, CD43, CD8, CD7, CD4, and CD3 inhibited galectin-1 binding to 
the cells (107). Separation of the galectin-1 binding glycoproteins directly from membrane 
proteins of MOLT-4 cells was performed by Triton X-100 extraction and subsequent galectin-
1 affinity chromatography (107). The isolated proteins: CD45RA, CD45R0, CD43, CD4, 
CD7, actin, and the proteins of CD3 complex. Only three galectin-1 binding proteins were 
isolated from ARR cells, CD45R0, CD43, and CD7 (107). Because the ARR cell line is 
susceptible to galectin-1 (107), these data suggested that CD4, CD3, and CD8 are not 
involved in the death signal and, at most, CD45, CD43, and CD7 are directly involved in 
delivering the death signal following galectin-1 binding. The coimmunoprecipitation 
experiment indicated that CD45, CD43, and CD7 are either the primary or the most accessible 
glycoprotein receptors for galectin-1 on the cell surface, implying that galectin-1 death 
involves one or more of these three glycoproteins (107). The relevance of CD45 in mediating 
apoptosis was supported by the fact that CD45-positive Jurkat T cells were more susceptible 
to the apoptotic effect than were CD45-negative cells (84, 108). It was later shown that CD45 
does not mediate the apoptotic signal of galectin-1 in T cells (109). Binding of the lectin leads 
to a decrease in phosphatase activity of CD45 and downregulation of Src kinase Lyn (Fig.1.5) 
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(110) that could lead to various downstream effects. Further investigation revealed that CD7 
delivered the apoptotic signal of galectin-1. HUT78 cells, not sensitive to galectin-1 and not 
expressing CD7, were transfected with CD7 cDNA (110). CD7 expression rendered the cells 
sensitive to galectin-1 induced apoptosis (111). 
 
CD4
CD45
CD7TCR/CD3/ξTCR/CD3/ξ
Zap-70
Lck Lck
Galectin-1
Decrease of the
phosphatase activity
Lyn kinase downregulation
Partial ξ-chain phosphorilation
no IL-2 production and
prolipheration
?
Apoptosis
 
Fig.1.5. Galectin-1 binding molecules on T cell surface and mechanisms of modulation of 
lymphocyte signalling and apoptosis induction (from Ref. 112 with modifications). 
 
It was demonstrated that binding of galectin-1 to T cells results in a dramatic 
redistribution of CD3, CD7, CD43, and CD45 into segregated membrane microdomains on 
the cell surface (111). Whereas CD45 and CD3 colocalize on apoptotic blebs, CD7 and CD43 
are distributed in small patches away from the membrane blebs (111). The galectin-1-induced 
CD45 sequestration could functionally remove and/or inhibit the protein tyrosine phosphatase 
domain of CD45 from a pro-apoptotic signaling complex. Because susceptibility to galectin-1 
induced apoptosis may be regulated by the presentation of lactosamine on the specific 
oligosaccharide structures created by the glycosyltransferase enzymes, the requirement of 
these enzymes for the apoptotic process was investigated. Galvan and coworkers 
demonstrated that expression of the core 2-beta-1,6-N-acetylglucosaminyltransferase 
(C2GnT) is necessary to create a branched structure on the O-glycans of T-cell surface 
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receptors and is critical for galectin-1 to kill activated T cells (113). Overexpression of 
C2GnT increased the susceptibility of double-positive thymocytes to galectin-1 death signals 
(113). 
Investigations were performed regarding the downstream mechanisms of signal 
transduction induced by galectin-1. A marked increase in the binding of nuclear extracts to 
synthetic oligonucleotides containing the activator protein 1 (AP-1) consensus sequence, was 
detected by an electrophoretic mobility shift assay, when T cells were cultured for 30 min in 
the presence of the galectin-1 (114). This DNA-binding activity was preceded by a rapid 
increase in the levels of c-Jun mRNA, as determined by Northern blot analysis. Evidence was 
also provided by Western blot analysis, showing that galectin-1 inhibits Concanavalin A (Con 
A) induction of Bcl-2 expression (114). These facts suggest that apoptosis induced by 
galectin-1 requires the activation of the AP-1 transcription factor and modulation of Bcl-2 
protein expression (114). Two mutant Jurkat cell lines, lacking the p56lck (JCaM) or the 
ZAP70 (P116) kinases, did not respond with tyrosine phosphorylation upon galectin-1 
treatment and they were much less sensitive to galectin-1 induced apoptosis (R.Fajka-Boja, 
unpublished observation). Recent studies have provided evidence that galectin-1 cooperates 
with T cell antigen receptor (TCR) engagement to enhance extracellular signal-regulated 
kinase-2 activation in a T-cell hybridoma and freshly isolated mouse thymocytes (106). It was 
proposed that galectin-1 acts as a partial ligand that antagonizes TCR responses known to 
require costimulation and complete tyrosine phosphorylation, such as IL-2 production, but 
permits those TCR responses that require only partial signals, such as CD69 up-regulation and 
apoptosis (Fig.1.5) (115). 
 
1.4.1.1. Extracellular function of galectin-1 in the immune system 
 
Role of galectin-1 in the generation of immunological tolerance 
An important role of galectin-1 is that it participatesc in the generation of central and 
peripheral tolerance utilizing its growth inhibitory and apoptotic properties (Fig.1.6). Human 
thymic epithelial cells express galectin-1, which binds to core 2-O-glycans on immature 
cortical thymocytes and modulates their survival (105). Galectin-1 binding correlates with the 
activation state of the cells, as immature cortical thymocytes bind more galectin-1 than mature 
medullar thymocytes (105) due to different glycosylation patterns in the cell populations. 
Galectin-1 killed non-selected and negatively selected immature thymocytes (105). Induced 
apoptosis was independent of that induced by steroids, but was synergistic with TCR 
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engagement (105). In this sense the epithelial lectin participates in positive and negative 
selection growth and cytotoxic signals in the thymus. 
 
Fig.1.6. Role of apoptotic function of galectin-1 at the central and peripheral levels of the adaptive 
immune response (from Ref. 116 with modifications). 
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The peripherial T cells are also exposed to the cytotoxic effect of galectin-1 as has 
been shown in in vitro experiments. It shows specific growth inhibitory properties towards 
different cell types, such as phytohemagglutinin (PHA)-activated human T cells (117,118), 
concanavalin (ConA)-stimulated rat T cells (119), activated chicken lymphocytes (120), 
human leukemia T cells (121). Following an antigenic challenge, galectin-1 is secreted from 
activated T cells and reduces clonal expansion of antigen-stimulated CD8+ T cells and IL-2 
production in an autocrine manner (106, 122, 117, 118). It has been demonstrated that under 
certain inflammatory conditions, activated macrophages (104, 123), antigen-stimulated T cells 
(118), activated B cells (98) and alloreactive T cells (124) secrete high level of galectin-1, and 
downregulate the immune response. 
The immunosuppressive and anti-inflammatory effects of galectin-1 have been 
demonstrated in several experimental models of autoimmunity and chronic inflammation. 
Galectin-1 ameliorates phospholipase A2-induced edema in a selective and dose-dependent 
manner, when pre-injected or co-injected together with the enzyme (125). The lectin inhibits 
the release of arachidonic acid and prostaglandin production from lipopolysaccharide-
stimulated macrophages and blocks neutrophil extravasation, mast cell degranulation and 
nitric oxide synthesis (125). It prevents clinical and histopathological manifestations of 
autoimmune encephalomyelitis (EAE) (126), ameliorates the inflammatory and autoimmune 
response in collagen-induced arthritis by increasing T cell susceptibility to activation induced 
cell death (AICD) (122). Galectin-1 pre-treatment prevented both liver injury and T cell liver 
infiltration induced by ConA (127). This immunosuppressive effect was associated with the 
inhibition of TNF-α and TNF-γ production. Galectin-1 purified from electric eel prevented the 
development of experimental autoimmune myasthenia gravis in rabbits (128). 
Galectin-1 is expressed in immune privileged tissues, such as retina (129), placenta 
(130-133), testis (134, 135) and ovary (60, 136). Immune privileged tissues do not encounter 
the differentiating immune cells, therefore they are potential targets for the immune response. 
They have to protect their integrity, prohibiting the survival and proliferation of specific 
lymphocytes and thereby the inflammation reaction in these tissues. Galectin-1 might 
contribute to immune privileged mechanisms, ensuring the rapid elimination of the 
autoreactive T-cells by an apoptotic pathway. 
Questions remain open about the mechanisms of the galectin-1 function in the immune 
system. One of the most important is the involvement of its sugar binding activity in 
extracellular function, particularly in the induction of apoptosis. As has been mentioned 
above, T cells lacking C2GnT are resistant to galectin-1 induced cell death (113). This 
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enzyme is responsible for creating the branched structure on O-glycans of T cell surface 
glycoproteins (137). Blocking of the CRD by lactose gives controversial results, inhibiting 
(84) or not inhibiting (R.Fajka-Boja, unpublished observation) the lectin induced apoptosis. 
Experiments where the lectin CRD specificity is abolished would give additional valuable 
data on importance of sugar binding in the induction of apoptosis. 
 
1.4.2. Intracellular function of galectin-1 
In spite of the more or less well characterized functions of secreted galectin-1, its 
intracellular function remains poorly defined. The lectin has been implicated in the regulation 
of the membrane localization of oncogenic H-Ras(12V) (138). Overexpression of galectin-1 
results in cell transformation, while antisense RNA inhibits such transformation (138). 
Farnesylthiosalicylic acid, which disrupts Ras membrane anchorage, disrupts H-Ras(12V)-
galectin-1 interactions as well (138). Further studies demonstrated that the lectin diverts the 
Ras signals to Raf-1 at the expense of PI3 kinase (139). 
Galectin-1 is also involved in pre-mRNA processing. Nuclear extracts (NE) from 
HeLa cells used for cell free splicing assays contain galectin-1 (140). Depletion of galectin-1 
and galectin-3 from NE inhibits splicing, and reconstitution of the proteins reconstitutes 
splicing activity (140). A component of the splisosome complex, Gemin4 has been shown to 
interact with galectin-1 in this process (139). This function is inhibited by lactose (139). 
Intracellular galectin-1 has also been shown to promote proliferation of human neuroblastoma 
cells by an unknown mechanism (141). 
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2. Aims of the study 
 
Our aim was to study two principal aspects of galectin-1 function: 
1. It has not been clearly defined whether the carbohydrate binding of galectin-1 is 
essential for the apoptotic function of the protein. The main reason for this is that the 
purification of the non-binding mutants with classical sugar-matrix affinity chromatography 
encountered difficulties. Therefore our purpose was: 
a) To establish a system that would provide a way to isolate this kind of mutant 
 proteins. 
b) To analyse whether or not mutants characterized previously as sugar “non-binding” 
 are able to trigger apoptosis of T lymphocytes. 
c) To investigate how particular mutations of amino acids, that directly bind 
 carbohydrate, affect galectin-1 induced apoptosis. 
 
2. To obtain a deeper insight into the intracellular function of galectin-1 we have also 
 asked the questions: 
a) How de novo expressed galectin-1 modulates T cell function? 
b) What is the role of the lectin property of galectin-1 in intracellular function? 
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3. Materials and Methods 
 
3.1. Recombinant protein production 
Human wild type and mutant galectin-1 cDNAs (GAL1) were a generous gift from J. 
Hirabayashi and K. ichi Kasai Teikyo University, Japan (61). Figure 3.1. shows the sequence 
of the protein and the positions of the mutations. Wild type and R48H (Arg48 changed to 
His), E71Q (Glu71 changed to Gln), R73H (Arg48 changed to His) mutant GAL1s were 
excised from pUC540 vector with NcoI, and inserted into a bacterial expression vector 
pETHis (142) at the NcoI site, in the sense direction. The resulting protein has a His6 tag at the 
N-terminus and three linker amino acids. The His tag allows for affinity purification of the 
proteins on a Ni-resin. Wild type GAL1 cDNA, after excision from pUC540, was also 
inserted into bacterial expression vector pQE60 (QUIAGEN, Hilden, Germany) at the NcoI 
site. The proper orientation of the cDNA inserts was confirmed by restriction enzyme 
analysis. Quality of the cloning and “in frame” position of the His6 tag in pETHis vector was 
confirmed by sequencing. 
 
Fig.3.1. Protein sequence of galectin-1 with indicated mutations. Each mutated version of galectin-1 
carries one of the substitutions. 
 
GAL1 subcloned to pQE60 or to pETHis was transformed into BL-21 (BF-dcm ompT 
hsdS(rB
-mB) gal λ(DE3)) (Stratagene), inoculated from a single colony into 2ml of LB 
medium containing 200 μg/ml ampicillin, and grown overnight. The obtained culture in 
1:1000 dilution was inoculated in LB medium containing 200 μg/ml ampicillin and grown for 
8 hours at 370C. 
 
3.2. Purification of recombinant galectin-1 (rGal1) 
200ml of bacterial culture producing rGal1 was centrifuged at 2500g for 30 min at 40C 
in a Sorvall RC3B centrifuge, washed twice with 80ml of lysis buffer  (2500g 15 min, 40C, 
Hettich Universal 30RF, rotor 1424A) containing 4 mM beta-mercaptoethanol, then disrupted 
at 40C by “French” press (AMINCO, Maryland, USA) in 50ml of lysis buffer supplemented 
ACGLVASNLN LKPGECLRVR GEVAPDAKSF VLNLGKDSNN LCLHFNP(R48H)FN 
AHGDANTIVC NSKDGGAWGT (E71Q)Q(R73H)EAVFPFQ PGSVAEVCIT FDQANLTVKL 
PDGYEFKFPN RLNLEAINYM AADGDFKIKC VAFD 
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with 1 mM PMSF. All following steps were done at 40C. The lysate was spun at 10 000g for 
30 min, the supernatant was filtered through GF/C membrane, and loaded on an alpha-lactose 
gel (EY Laboratories) column pre equilibrated with 20ml of lysis buffer supplemented with 
1mM PMSF and 4mM beta-mercaptoethanol. The lysate was recirculated three times and the 
bound protein was washed with 20 ml of washing buffer  supplemented with 0,25 mM PMSF 
and 4mM beta-mercaptoethanol. Protein was eluted with 20ml of elution buffer  
supplemented with 0,1M iodoacetamide, and 1ml fractions were collected. Eluted fractions 
were analyzed on sodium dodecyl sulfate 12% polyacrylamide gel electrophoresis 
(SDS/12%PAGE) and dialyzed against phosphate buffered saline (PBS)  containing 100 μM 
beta-mercaptoethanol. Protein concentration was estimated with Bradford assay reagent 
(Biorad) and by the absorbance at 280nm. 
 
3.3. Purification of recombinant His-tagged galectin-1 (rHisGal1) 
200ml of bacterial culture producing rHisGal1 or its mutants was processed as 
described in section 3.2. All following steps were done at 40C. Lysate was spun at 10 000g for 
30 min, supernatant was filtered through GF/C membrane (Whatman), and supplemented with 
iodoacetamide to final concentration of 0,1M. Then the lysate was loaded onto a Ni-NTA-
agarose (Invitrogen) column pre equilibrated with 20ml of lysis buffer  supplemented with 
1mM PMSF. It was recirculated three times and washed with 20ml of washing buffer  
containing 0,1 M iodoacetamide. Bound protein was eluted with 20ml of elution buffer . 
Collected 1ml fractions were tested on SDS/12%PAGE and dialyzed against PBS containing 
100μM beta-mercaptoethanol. Protein concentration was estimated with Bradford assay 
reagent (Biorad) and by the absorbance at 280nm. 
 
3.4. Alpha-lactose binding assay 
Purified recombinant wild type rHisGal1 and its mutants in PBS containing 100μM 
beta-mercaptoethanol were incubated with alpha-lactose gel (EY Laboratories) at 40C for 1 
hour on a rotating platform, washed with washing buffer  three times. Resin, together with 
bound protein, was subjected to SDS/12%PAGE and Western blotting (see below) with rabbit 
anti-galectin-1 antibody produced in our laboratory. 
 
3.5. Cell Culture and transfection 
The human Jurkat T cell line was cultured in RPMI 1640 (GIBCO) tissue culture 
medium supplemented with 5% heat inactivated FCS and glutamine . Human embryonic 
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kidney epithelium based cell lines ProPak-A (PPA) (143) and Phoenix gp (generous gift of G. 
Nolan) were cultured in DMEM (Life Technologies, Gaithersburg, MD) supplemented with 
10% heat inactivated FCS and glutamine . All cell lines were maintained at 37°C in a 
humidified atmosphere of 95% air and 5% CO2. GAL1 and mutant (R48H) GAL1 cDNA 
were excised from pETHis with BamHI/NcoI, and ligated into EcoRI/BamHI treated 
mammalian expression vector pLXSN together with preannealed oligonucleotides (G-
1.Kozak"+": 5’ - AAT TCT CTT CGC TTC AGC TTC AAT - 3'; G-1.Kozak"-"5' - CAT 
GAT TGA AGC TGA AGC GAA GAG - 3'). The proper orientation and position of the 
cDNA inserts was confirmed by restriction enzyme analysis and sequencing. Phoenix gp cell 
line was transfected by conventional Ca/phosphate method (144) with obtained constructs 
together with pCiGLwt vector containing viral envelope cDNA (kindly provided by G. 
Veres). Virus containing supernatant was collected 48 hours after transfection, filtered 
through 0.45 m filter (Corning, SFCA membrane) and used for infection of PPA cells by 
centrifugation (145) in the presence of 4g/ml polybrene. Infected PPA cells were selected on 
400g/ml of G418 (Invitrogen) for two weeks. Selected cells were grown to confluence, and 
supplied with a fresh medium. Cells were fed with fresh medium and supernatant was 
collected after 16 hours culture. The Jurkat cells were transduced by centrifugation at 1000g 
for 90 minutes with virus containing supernatant (146) in presence of 4g/ml polybrene and 
selected for two weeks on 1mg/ml of G418. Protein expression was analyzed by Western 
blotting (section 3.6). 
 
3.6. Western blotting 
Triton X-100 soluble extracts prepared from 2105 Jurkat cells per sample or proteins 
after binding to alpha-lactose gel (EY Laboratories) were separated on a SDS/12%PAGE and 
transferred to nitrocellulose membrane (Schleicher & Schuell) in transfer buffer . The 
membranes were blocked using Tris buffered saline (TBS) containing Tween20 (TBST) , 3% 
Teleostean gelatin and subsequently probed with 20μg/ml of rabbit anti-galectin-1 antibody in 
TBST for 1 hour at 40C and with 275μg/ml biotinylated goat anti-rabbit IgG (DAKO) in 
TBST for 1 hour at 40C, and then with 18,75 μg/ml streptavidin-HRPO conjugate (DAKO) in 
TBST for 1 hour at 40C. Immunoreactive proteins were visualized by an enhanced 
chemiluminescence (ECL plus) detection system (Amersham Pharmacia Biotech). Prestained 
molecular weight marker was purchased from GIBCO-BRL. 
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3.7. Indirect immunofluorescence 
Jurkat cells were washed once in PBS, then incubated for 1 hour at 40C in PBS 
containing 20g/ml of the indicated monoclonal antibody, washed three times with cold PBS 
containing 0,1% NaN3, and then incubated for 30 min at 4
0C with goat anti-mouse FITC 
conjugate. Finally, the cells were washed three times with cold PBS containing 0,1% NaN3 
and subjected to cytofluorimetric analysis with FACScalibur (Becton Dickinson). The dead 
cells were discriminated by propidium iodide (PI) uptake (1μg/ml) prior measurement. 
 
3.8. Assays for cell growth 
To assess the growth and proliferation of Jurkat transfectants, cells were plated at a 
density of 105 cells/ml in RPMI 1640 medium containing 5% FCS in triplicates. Viable cell 
numbers were determined on day 4 after plating by the 1-(4,5-Dimethylthiazol-2-yl)-3,5-
diphenylformazan (MTT) assay (145) and by trypan blue exclusion counting. MTT assay is 
based on a reduction of tetrazolium salt to formazan by mitochondrial dehydrogenase. It was 
performed as follows. MTT solution was added to each sample to a final concentration of 
1mg/ml. Samples were incubated for 4 hours at 370C then the medium was removed and a 
solution of 0,05M HCl in isopropanol was added for 10 min to solubilize formazan crystals. 
Absorbance of the samples was measured at 570nm. Trypan blue exclusion counting was 
performed as follows. Cell suspension was diluted 1:10 in trypan blue solution for cell 
counting and the living cells were discriminated by trypan blue exclusion. Average, standard 
deviation, and Student test parameters were calculated. 
 
3.9. Cell cloning 
The Limiting dilution method was used for cloning. Transfected cells were diluted to 
10, 100, 1000 cells/ml in RPMI 1640 tissue culture medium supplemented with 5% FCS and 
antioxidants (147) , then plated in 96-well flat bottom plates in 100 μl/well. After three weeks 
growing colonies were expanded and analyzed. 
 
3.10. Measurement of intracellular Ca2+ concentration 
Jurkat cells were suspended in 107 cells/ml concentration in RPMI-1640 supplemented 
with 5% FCS and incubated with 7.5 µM of Fluo-3AM and 7.5 µM of FuraRed-AM 
(Molecular Probes, Eugene, OR, USA) for 30 min at 37°C. Cells were then adjusted to a final 
concentration of 5x105 cells/ml with the addition of cell culture medium and incubated for a 
further 30 min at 37°C. The cells were washed twice with RPMI and resuspended in fresh cell 
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culture medium at a concentration of 106 cell/ml. Intracellular Ca2+ was measured using 
FACScalibur (Becton Dickinson) and data were presented as the ratio of Fluo-3 and FuraRed 
fluorescence intensity at 530 and 650 nm, respectively, versus time. 
 
3.11. Apoptosis assay 
For the apoptosis assay we used cytofluorimetric analysis of the DNA content and 
sub-G1 cell population was considered as apoptotic cells. The cells (1-3 106 cells/ml) were 
treated with various apoptosis inducing agents for 16 hours in RPMI 1640 medium containing 
2% FCS in a CO2 thermostat. After washing with PBS, the cells were resuspended at a 
concentration of 1×106 cells/ml with staining solution . The samples were then incubated at 
room temperature for 20 min in the dark and analyzed by flow cytometry (FACScalibur; 
Becton Dickinson). CellQuest (Becton Dickinson) and ModFit LT (Verity Software House, 
Topsham, ME) were used for the analysis. 
 
3.12. Binding assay to cell surface glycoconjugates 
Jurkat cells were incubated for 1 hour at 40C in PBS containing 25g/ml of rHisGal1 
or its mutants, then washed with cold PBS or PBS containing 100mM lactose and incubated 
further at 40C in PBS containing 20μg/ml of rabbit anti-galectin-1 antibody for 30 minutes. 
After washing with cold PBS containing 0,01% of NaN3, the cells were stained with 20μg/ml 
of goat anti-rabbit biotin conjugate (DAKO) in PBS at 40C for 30 min, then it was washed out 
and they were stained with the 2μg/ml of streptavidin-FITC in PBS for 30 min. Finally, the 
cells were washed three times with cold PBS containing 0,01% NaN3 and subjected to 
cytofluorimetric analysis with FACScalibur (Becton Dickinson). Propidium iodide was added 
to cells to the final concentration of 1μg/ml to discriminate the dead cells. 
 
3.13. Mitochondrial dehydrogenase activity assay 
The cells were plated in triplicates at a concentration 106 cells/well in flat bottom 96-
well plates in RPMI supplemented with 5% FCS and glutamine. MTT assay was performed as 
described in the section 3.8. 
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4. Results 
 
4.1 Role of the carbohydrate-binding activity in the extracellular function of 
galectin-1 
4.1.1. rGal1 induced apoptosis is not diminished by lactose 
To test if, in our system, apoptosis induced by galectin-1 could be inhibited by lactose, 
we performed the following experiment. Jurkat cells were treated with rGal1 for 24 hours in 
the presence or absence of 100mM lactose and apoptosis was estimated by measuring the 
DNA content (Fig. 4.1). Apoptosis induced by rGal1 was not significantly inhibited by 
lactose. 
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Fig.4.1. FACS analysis of the DNA content of PI stained Jurkat cells (see section 3.11 for 
details) after incubation for 24 hours with a dilution of the PBS containing 100M beta-
mercaptoethanol for control (A), or with 100mM lactose (B), or with 25g/ml of the rGal1 in 
abscence(C) or presence of lactose (D) is shown. 
 
4.1.2. rHisGal1 is purified on Ni-NTA agarose resin 
Galectin-1, mutated at the sites responsible for direct binding to its ligands, were 
obtained from J. Hirabayashi and K. ichi Kasai Teikyo University, Japan (61, 63). We 
subcloned wild type cDNA and cDNA of the R48H, E71Q, R73H mutants into pETHis 
vectors in order to be able to purify the recombinant proteins via His6-tag independently of 
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their carbohydrate-binding activity. Wild type and mutant proteins were named rHis-Gal1 for 
wild type, rHisGal1.71 for E71Q, rHisGal1.73 for R73H, rHisGal1.48 for R48H. SDS 
12%PAGE analysis of the purification fractions of recombinant proteins is shown on Fig. 4.2. 
 
 
4.1.3. Rabbit anti-galectin-1 antibody recognizes both His-tagged and non-His-
tagged galectin-1 and its mutants 
The wild type rHisGal1 and the mutants contain an extra nine amino acids, six 
histidines and three linker amino acids, in the protein sequence compared to the non-His-
tagged rGal1. To test whether the extra sequence affected the antigenic properties of 
rHisGal1, we performed immunoblotting analysis using rabbit anti-galectin-1 antibody 
(Fig.4.3). The antibody equally recognized both proteins. This suggested that the antigenic 
properties of rHisGal1 were not changed compared to rGal1 and the antibody can be used to 
detect rHisGal1. 
14kDa
 
Fig.4.2. 1 - bacterial lysate, 2 – flow through after binding to the resin, 3 – 6 elution fractions: 3 - 
rHisGal1, 4 -  rHisGal1.48, 5 - rHisGal1.71, 6 - rHisGal1.73 
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Fig.4.3. Rabbit anti-galectin-1 antibody recognizes rHisGal1. rGal1 (1,3) and rHisGal1(2,4) 
were run on a SDS/12%PAGE, transferred onto a nitrocellulose membrane and stained with control 
rabbit IgG (1,2) or rabbit anti-Gal1 (3,4) antibody (see section 3.6. for details). 
 
Antigenic properties of the recombinant His-tagged mutants were tested in comparison 
to wild type rHisGal1 with Western blotting (Fig. 4.4.). The antibody to rGal-1 recognized the 
mutant rHis-Gal1 proteins similarly to the wild type protein. 
14kDa
 
Fig.4.4. The proteins were separated on a SDS12%PAGE, transferred onto a nitrocellulose filter and 
hybridized with rabbit anti-galectin-1 antibody: 1 – rHisGal1.71, 2 – rHisGal1.73, 3 – rHisGal1.48, 4 
– rHisGal1. 
 
4.1.4. rHisGal1 binds to lactose and cell surface glycoproteins, and induces 
apoptosis of Jurkat cells 
To test whether addition of the His-tag affected the biological activity of rHisGal1, we 
compared the lactose binding ability of rGal1 and rHisGal1. As it is shown on Fig.4.4. 
rHisGal1 bound to lactose. 
  1  2    3  4 
 
14 kDa 
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Fig 4.5. Recombinant proteins were subjected to alpha-lactose binding assay, then alpha-
lactose-bound proteins were eluted in SDS sample buffer, run on a SDS/12%PAGE, transferred to a 
nitrocellulose membrane, and blotted with anti-galectin-1 rabbit antibody. 1 - rGal1, 2 - rHisGal1. 
 
Both proteins, rGal1 and rHisGal1, bound to the surface glycoconjugates of Jurkat 
cells as was shown by indirect immunofluorescence staining (Fig. 4.6). 
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Fig.4.6. Jurkat cells were incubated with a protein to be bound, stained with anti-galectin-1 
rabbit antibody, then with goat anti-rabbit biotin conjugate and streptavidin FITC. The percentage 
of cells that bound rGal1 or rHisGal1 is shown. 
 
Apoptosis inducing ability of rHisGal1 was not affected by the his-tag and was similar 
to that of rGal1 (Fig. 4.7) 
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Fig.4.7. FACS analysis of the DNA content of PI stained Jurkat cells (see section 3.11 for 
details) after incubation for 16 hours with a dilution of the PBS containing 100M beta-
mercaptoethanol for control , or with 25g/ml of the recomninant proteins is shown. A – apoptosis 
induced by rGal1, B - apoptosis induced by rHisGal1. 
 
4.1.5. rHisGal1 mutants, R48H, E71Q, R73H, have reduced or abrogated ability to 
bind alpha-lactose, no binding activity towards cell surface glycoconjugates, and have 
reduced or abrogated ability to induce apoptosis 
 
To test the ability of rHisGal1 and the mutants to bind lactose, we performed an alpha-
lactose binding assay (see section 3.4 for details). As Fig.4.8 shows, rHisGal1.71 and 
rHisGal1.73 had a slightly reduced and rHisGal1.48 an abrogated lactose-binding activity. 
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Recombinant wild type and mutant proteins were tested for their ability to bind to cell 
surface glycoconjugates of Jurkat cells. The “non-binding” mutants, rHisGal1.73, 
rHisGal1.71, and rHisGal1.48 did not bind to the cells (Fig.4.9). Cell bound galectin could be 
washed off by PBS containing 100mM lactose (data not shown). 
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Fig.4.9. Jurkat cells were incubated with a protein to be bound, stained with anti-galectin-1 
rabbit antibody, then with goat anti-rabbit biotin conjugate and streptavidin FITC. The percentage of 
the cells that bound a protein is shown. A – binding of rHisGal1.71 and rHisGal1.73; B – binding of 
rHisGal1.48. 
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Fig. 4.8. Recombinant proteins were subjected to alpha-lactose binding assay and then 
alpha-lactose-bound proteins were eluted in SDS sample buffer, run on a SDS/12%PAGE, 
transferred to a nitrocellulose membrane, and blotted with anti-galectin-1 rabbit antibody. 1 - 
rGal1.71, 2 - rHisGal1.73, 3 - rHisGal1.48, 4 - rHisGal1. 
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Apoptosis inducing ability of the recombinant wild type and mutant proteins was 
tested on Jurkat cells. Recombinant HisGal1 and rHisGal1.73 induced apoptosis, although 
rHisGal1.73 triggered a lower level of apoptosis. Recombinant HisGal1.48 did not induce a 
significant degree of apoptosis (Fig. 4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.10. FACS analysis of the DNA content of PI stained Jurkat cells (see section 3.11 for 
details) after incubation for 16 hours with a dilution of the PBS containing 100M beta-
mercaptoethanol as the control , or with 25g/ml of the recombinant proteins, is shown. The 
percentage of apoptotic cells is indicated. 
 
4.2. An intracellular function of galectin-1 
Intracellular function and possible connection of this function and the sugar-binding 
ability of galectin-1 is poorly or not studied. We subcloned wild type or mutant (R48H) 
GAL1 into the mammalian retroviral expression vector, pLXSN, and transfected the 
constructs into Jurkat cells, that do not express endogenous galectin-1. 
 
4.2.1. Galectin-1 expression in stably transfected Jurkat cells 
For the investigation of intracellular function of galectin-1 and its dependence on 
carbohydrate binding activity, we transfected Jurkat cells with wild type and R48H mutant 
galectin-1 using retroviral transfection (see section 3.5. for details). The mutant R48H has no 
ability to bind its carbohydrate ligands (Fig. 4.8 and 4.9). In the control, Jurkat cells were 
transfected with an empty vector. The transfectants were named: Jmock – for Jurkat transfected 
with pLXSN vector, Jgal – for Jurkat transfected with galectin-1 cDNA cloned into pLXSN vector, 
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and Jgal48 – for Jurkat transfected with R48H mutant galectin-1 cDNA cloned into pLXSN vector. 
After selection of the transfected cells expression of galectin-1 was detected by Western 
blotting (Fig. 4.11, A) using rabbit anti-galectin-1 antibody. Later on, the selected cells were 
cloned. 60 clones of the Jmock cells, 59 clones of the Jgal cells, and 56 clones of the Jgal48 
cells were obtained. The clones were analysed by Western blotting for galectin-1 expression 
(data not shown). Western blotting analysis of the clones selected for further experiments is 
shown in Fig. 4.11, B. 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.11. Wild type and mutant galectin-1 are expressed in transfected Jurkat cells. Western 
blotting analysis with rabbit anti-galectin antibody is shown. A – uncloned transfectants; 1 and 2 - two 
independent transfections; B - analysis of the selected cloned transfectants: 5c11 and 5h12 – Jmock 
clones; 3f6 and 3g6 - Jgal clones, 8e10 and 8g12 - Jgal48 clones. 
 
4.2.2. Galectin-1 is not present on the surface of transfected cells 
In order to determine whether galectin-1 is present on the surface of expressing cells, 
we performed indirect immunofluorescence staining of the surface proteins with the rabbit 
anti-galectin-1 antibody (Fig. 4.12). The exogenously added rGal1 was bound to the surface 
of Jurkat cells (Fig. 4.12, A). However galectin-1 produced by the transfectants did not appear 
on the surface of Jgal cells (Fig. 4.12, C). Jmock cells were used as negative control (Fig. 
4.12, B). 
    Jmock        Jgal        Jgal48 
 5c11 5h12   3f6   3g6   8e10  8g12 
 
   Jmock       Jgal          Jgal48 
   1     2      1       2        1      2 
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Fig.4.12. The cells were treated (A) or were not treated (B, C) with 25μg/ml of rGal1 then 
stained with anti-galectin-1 rabbit antibody, then with goat anti-rabbit biotin conjugate and 
streptavidin FITC (see sections 3.7 and 3.12 for details) and analysed by a cytofluorimeter. The thin 
line is a control treatment with rabbit IgG, the thick line is a sample treated with rabbit anti-galectin-1 
antibody. A - rGal1 bound to the surface of Jurkat cells; B – Jmock; C - Jgal. Increase in fluorescence 
intensity is indicated in percent. 
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4.2.3. Presence of intracellular galectin-1 influences the proliferation of Jurkat cells 
Both Jgal and Jgal48 showed significantly lower proliferation compared to the Jmock 
cells (Fig. 4.13) in a four day proliferation assay. The result was obtained with two different 
methods. The MTT assay (Fig. 4.13, A) represents the metabolic activity of the living cells, 
and the trypan blue exclusion assay (Fig. 4.13, B) shows the number of the viable cells. 
Expression of the wild type galectin-1 in the Jurkat cells resulted in a more dramatic effect on 
proliferation then did the mutant protein, since galectin-1 caused a 38% decrease while the 
mutant only a 20% decrease in the cell division compared to the proliferation of mock 
transfected cells measured with MTT. 
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Fig.4.13. The cells expressing wild type galectin-1 have changed proliferation activity. A - 
MTT assay, optical density at 570 nm wave length was measured on day 0 and day 4; B - the cell 
counting by trypan blue exclusion method, cells were counted at day 0 and day 4. Significant 
difference (n=3, P<0,01) between Jmock and other transfectants is marked with a star. 
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4.2.4. Galectin-1 expression upregulates cell surface level of TCR 
Expression of the surface molecules determines T cell function. We examined the 
expression of the most important surface markers. The expression levels of CD45, CD95, 
CD2, LFA-1, and MHC1 were not changed on Jgal compared to Jmock, as was shown by the 
indirect immunofluorescence labeling with respective antibodies (Fig. 4.14). In contrast, TCR 
expression level was upregulated by galectin-1 expression as Fig. 4.15 shows. Expression of 
the mutant galectin-1 in the Jurkat cells resulted in an intermediate elevation of TCR 
expression between the TCR level of mock and wild type galectin-1 transfected cells (Fig. 
4.15). 
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Fig.4.14. Expression of the examined T cell surface markers on Jgal cells is not changed in 
comparison to Jmock. Thin line – Jmock, thick line –Jgal. FACS analysis of the indirect immuno 
fluorescence labeling with respective antibodies is shown. 
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Fig.4.15. T cell antigen receptor expression level is higher on Jgal in comparison to Jmock 
and Jgal48. A-C – clones 5h12 for Jmock (thin line); 3g6 – for Jgal (thick line); 8g12 - for Jgal48 
(dashed line); D-F – clones 5h12 for Jmock (thin line); 3f6 for Jgal (thick line); 8g10 for Jgal48 
(dashed line); A, D – histograms of staining only with anti-mouse-FITC conjugate; B, E – histograms 
of staining with monoclonal OKT3 antibody and with anti-mouse-FITC conjugate as a second 
antibody; C and F –percentage of TCR positive cells under the markers set on histograms B and E 
respectively. 
 
4.2.5.Ca2+ influx is affected by galectin-1 expression 
To analyse whether galectin-1 expression affected the TCR function, we performed 
the measurement of the intracellular Ca2+ concentration in response to TCR stimulation. 
Elevation of the intracellular Ca2+ concentration is one of the responses to stimulation of T 
cells through the TCR. The calcium acts as a second messenger molecule directly and 
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indirectly regulating the function of various proteins, such as calmodulin, calcineurin, 
transcription factors, and others. The Jmock, Jgal, and Jgal48 cells were activated via the TCR 
with anti-TCR antibody, OKT3 (Fig. 4.16, A, B). Clone 3g6 (Jgal) cells had a higher 
elevation of intracellular Ca2+ concentration in response to TCR stimulation then clones 5c11 
(Jmock) and 8g12 (Jgal48) (Fig. 4.16. A). The Jgal and Jgal48 transfected cells expressed 
higher level of TCR that the Jmock transfected cells (Fig. 4.15). To show whether the 
elevation of Ca2+ level is a result of this, we used a calcium ionophore, which acts 
independently of TCR in triggering Ca2+ influx. The calcium ionophore treatment resulted in 
Ca2+ elevation with a similar pattern to TCR stimulation (Fig. 4.16. C), indicating that Jgal 
cells give a higher response to the stimulations triggering Ca2+ influx. The increase of 
intracellular calcium concentration may come from two sources: the release of Ca2+ from 
intracellular stores or from the extracellular space. We added EGTA to the tissue culture 
medium to deplete the extracellular Ca2+ and to inhibit the latter source. Release from 
intracellular stores observed in absence of extracellular Ca2+ depleted by 5mM EGTA was 
also higher in 3g6 Jgal cells in either induced via the TCR or with calcium ionophore 
suggesting that Ca2+ comes from both sources (Fig. 4.13, B and D). Analysis of the second set 
of clones 5h12, 3f6, and 8e10 gave a similar result (data not shown). 
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Fig.4.16. The cells were loaded with Fluo3 and FuraRed as described in section 3.10, and anti-
TCR antibody (OKT3, 3μg/ml) (A and B) or calcium ionophore (C and D) were added in the abscence 
(A and C) or presence (B and D) of the 5mM EGTA. Elevation of Ca2+ concentration is plotted as 
ratio of FL1/FL3 against time. Thin line – 5c11 (Jmock), thick line – 3g6 (Jgal), dashed line – 8g12 
(Jgal48). 
 
4.2.6. Susceptibility to apoptosis is increased in Jurkat cells expressing galectin-1 
Galectin-1 induces apoptosis of activated T cells when applied extracellularly. It is not 
known, however, how endogenous expression of galectin-1 influences the susceptibility of T 
cells to apoptosis. We examined the transfected cells for their ability to respond to 
extracellular rGal1 stimulation. Treatment with recombinant galectin-1 induced a higher 
degree of apoptosis in cells expressing galectin-1 (Fig. 4.17). 
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Fig.4.14. Galectin-1-expressing cells are more susceptible to apoptosis induced by galectin-1. 
Jmock (A and B) and Jgal (C and D) cells were treated with PBS containing 100μM beta-
mercaptoethanol for the controls (A and C), or 25μg/ml of rGal1 (B and D), and DNA content was 
estimated as described in section 3.11. 
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 4.2.7. Mitochondrial activity is higher in the cells expressing galectin-1 
Mitochondria are a target for galectin-1 induced apoptosis, as was shown in our 
laboratory (G. Ion et al. unpublished observation). To examine whether endogenously 
expressed galectin-1 affected mitichondrial activity, a possible reason for the increased 
sensitivity to galectin-1 induced apoptosis of the Jgal cells, we analysed mitochondrial 
activity by labeling the cells with MTT. Expression of galectin-1 resulted in an increase in the 
activity of the mitochondrial dehydrogenase. 
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Fig.4.15. Jurkat cells expressing galectin-1 have an increased activity of mitochondrial 
dehydrogenase. The cells were plated at the same concentration of 106/ml, incubated in presence of 
1μg/ml MTT, lysed and colour was measured on 570nm wavelength, indicating the activity of 
the mitochondrial dehydrogenase (see section 3.13). 
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5. Discussion 
 
5.1. Role of the carbohydrate binding activity in the apoptotic function of galectin-1 
The previous data have suggested that galectin-1 induces apoptosis in a lactose 
inhibitable fashion (83). This was supported with the following observation: presence of 
lactose in concentration of 10mM inhibited calciunm signalling induced by galectin-1 in 
Jurkat cells (148). In contrast, we showed that the presence of the disaccharide competitor, 
lactose during the treatment of the cells with galectin-1 did not inhibit the cell death. To 
resolve this controversy between our and others’ results, we studied the role of sugar binding 
in the apoptosis using sugar “non-binding“ mutants of galectin-1. The three point mutants 
R48H, E71Q, R73H, generated by Hirabayashi et. al. (62, 64), have been described as unable 
to bind asialofetuin. Because these proteins could not be purified by the classical sugar 
affinity chromatography, they were not further analyzed for biological activity. In our 
experiments, the wild type, and mutant galectin-1 proteins were expressed in fusion with His-
tag and purified with Ni2+ affinity chromatography. In agreement with the results of 
Hirabayashi et al (62, 64), none of the mutants bound to cell surface complex 
glycoconjugates. However rHisGal71 and rHisGal73, but not rHisGal48 coupled to solid 
phase lactose, indicating that the former mutants retained the capacity to bind to a simple but 
not complex carbohydrates. This was a remarkable change in the specificity, since the wild 
type galectin-1 showed higher affinity toward complex sugars with two orders of magnitude, 
as to lactose (63). Analyzing the apoptotic effect of the mutants compared to the wild type 
protein, we found that the mutants retaining the affinity to lactose (e.g. rHisGal73) induced 
apoptosis, in contrast to the “null binding” form, rHisGal48. These findings can be explained 
in several ways: 1. The lectin property of galectin-1 contributes to the induced cell death, but 
the high affinity binding to complex sugars is not indispensable. 2. The receptor(s) 
transmitting the apoptotic signal by coupling to galectin-1 has not been characterized yet. The 
glycosphingolipid, lactosyl ceramide (CDw17) that contains disaccharide facing to the 
extracellular environment can be such a potential receptor. If this is the case we can 
understand why those mutants that bound to lactose but not to complex glycogonjugates, are 
able to stimulate apoptosis. On the other hand, the result that the presence of high 
concentration of lactose during induction of apoptosis does not support this theory. 
Although many galectin-1-binding cell surface glycoproteins were identified on T 
cells (107), olny CD7 was proposed as the one mediating the apoptotic signal. It is intriguing 
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whether lactosyl-ceramide can be the another “apoptotic receptor”. It is noteworthy that our 
latest results indicate that galectin-1 regulates cell viability via intracellular ceramide (an 
apoptotic sphingolipid second messenger) release. In the future we intend to investigate the 
binding the galectin-1 to lactosyl ceramide. 
 
5.2. Function and the role of the carbohydrate binding activity of intracellular 
galectin-1 
The intracellular function of galectin-1 have been much less studied than the 
extracellular one. Previous reports showed that the galectin-1 modulated the cell cycle, 
proliferation and viability of certain cell types. These activities were demonstrated by adding 
recombinant protein to the cell cultures and thus were likely to be exerted by an extracellular 
mechanism (102, 105, 84, 106). However the intracellular galectin-1 may also operate as an 
regulator of the above cell functions. It is not without examples in galectin family members: 
intracellular pro-apoptotic function was demonstrated for galectin-7, that is a prototype 
galectin similarly to gallectin-1. Galectin-1 and galectin-7 are not co-expressed in the same 
cells since the later is present mainly in keratinocytes. The overexpression of galectin-7 in 
keratinocytes and tumor cell lines increased their susceptibility to ultravioletB (UVB) or 
actinomycin-induced apoptosis (149). Upon UVB irradiation the amount of galectin-7 mRNA 
and protein dramatically increased and these cells were more sensitive to undergo apoptosis. 
In contrast to galectin-7, galectin-3 exerted an intracellular anti-apoptotic function, therefore 
cells overexpressing this protein were more resistent to apoptotic stimuli, such as UVB 
irradiation or cycloheximide/TNF treatment (150). 
To analyze the consequence of the expression of intracellular galectin-1 and to 
understand its possible function in T cells, we chose the approach transfecting Jurkat cells 
which did not express galectin-1 with either wild type or with “non-binding” mutant cDNA. 
The transfected cells produced but did not secrete the lectin. Expression of galectin-1 affected 
the proliferation rate in the following order: Jgal (expressing wild type galectin-) < Jgal48 
(transfected with carbohydrate non-binding mutant) < Jmock (transfected with empty vector). 
We characterized the tansfectants from the point of view of the modulation of different cell 
surface receptors. The pesence of the intracellular galectin-1 did not affect the expression of 
the investigated membrane proteins (CD45, CD95, CD2, LFA-1, MHC1), however the T cell 
receptor complex was upregulated highly in Jgal and to the lesser extent in Jgal48, compared 
to the mock transfected Jurkat cells. The increase of the membrane TCR level may result in 
the T cell responsiveness to TCR stimulation, as it has been shown in several studies (151-
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153). Indeed, when Jgal cells were activated with TCR antibody (that mimics the antigen), a 
higher elevation of the intracellular Ca2+ concentration occurred as compared to Jgal48 or 
Jmock. However the increase of the TCR level did not clearly explain the higher calcium 
response, because the Ca-ionophor that acts independently of the TCR also generated a 
similar pattern of Ca2+ signal as TCR stimulation did: the highest in Jgal, intermediate in 
Jgal48 and lowest in Jmock cells. 
The mechanisms that regulate Ca2+ signaling in T lymphocytes are diverse and 
complex. The events initiated by TCR ligation lead to inositol-1,4,5-trisphospate production 
and result in regulated release and influx of Ca2+ ions from the intracellular stores and from 
the extracellular space, respectively to the cytoplasm. The high intracellular Ca2+ 
concentration culminates in the activation of calcineurin and protein kinase C by 
Ca2+/calmodulin and Ca2+/diacylglycerol, respectively (154). Finally, calcineurin and the 
serine/threonine kinases activate a set of transcription factors that promote gene expression 
(154). It has been shown for B cells that different amplitude and duration of Ca2+ influx 
results in activation of distinct transcription factors (155). Similarly, the increased Ca2+ 
response in galectin-1 transfected Jurkat cells may direct the cells to different responses. 
Alternatively, the expression of galectin-1 in Jurkat T cells may decrease the treshhold for the 
same stimulus thereby increasing the sensitivity of the cells. 
Regarding the necessity of the carbohydrate binding activity of the intracellular 
galectin-1 we think that it is early to draw final conclusion from these experiments. The Jurkat 
cells transfected with the carbohydrate non-binding mutant galectin-1 gave a response 
between the wild type and mock transfected cell lines for the stimuli, including proliferation 
rate, Ca2+ signal to TCR or ionophore stimulation. The experiments carried out using 
uncloned cells, where the expression of the wild type and mutant proteins was on the same 
level, suggested that these effects of intracellular gal1 were at least partially dependent on the 
sugar binding activity. In the case of cloned transfectants, used for the TCR level 
determination and Ca2+ influx measurement, it is difficult to decide whether the effect is 
caused by absence of carbohydrate binding activity or lower expression of the mutant 
galectin-1 in Jurkat cells. 
Increased amplitude of the Ca2+ influx could also influence apoptotic signaling 
rendering the cells, expressing galectin-1, more sensitive to apoptosis (156). The addition of 
extracellular galectin-1 triggered a more remarkable cell death in Jgal cells compared with 
Jmock cells. The elevation of the sensitivity to galectin-1 induced apoptosis could be 
explained with the following findings: 1. We showed here, that the activity of the 
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mitochondrial dehydrogenase was higher in the Jgal than in the Jmock cells suggesting that 
there are more mitochondria in Jgal cells or the mitochondria are more active in this cells. 2. 
The galectin-1 induces apoptosis through the mitochondrial pathway as it was shown by G. 
Ion et. al (unpublished observation). 
Summarizing our results we following model. Intracellular expression of galectin-1 
has been shown to increase following antigenic stimulation of effector T cells (157). The 
galectin-1 is then secreted and induces apoptosis in an autocrine manner. In accordance with 
this, we found that activation of protein kinase C (PKC), that is an early consequence of TCR 
stimulation (158), results in augmenting the amount of intracellular and secreted galectin-1 
level (G. Ion et. al., unpublished observation) (see Fig. 5.1. A, B, and C as a model). If the 
stimulation of TCR and the activation of PKC are sustained, the apoptosis induced with the 
secreted or exogenously added recombinant galectin-1 will be inhibited (Fig. 5.1. D and C) as 
it has been shown by G. Ion et. al. (unpublished observation). If the other enviromental 
signals are appropriate (e. g. the TCR is downregulated after antigen stimulation and PKC is 
not activated), the galectin-1 induces apoptosis of activated and inflammatory T lymphocytes 
and therefore it can contribute to the peripheral T cell homeostasis and tolerance by 
eliminating these cells (see the model on Fig. 5.1. E). 
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Fig.5.1. Proposed model of the regulation of T cell function by galectin-1 (see text for 
details). 
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6. Concluding remarks 
 
1. To study the structure-function relationship of the extracellular galectin-1, we fused 
galectin-1 to His6-tag, cloned and expressed in E. Coli and purified with Ni
2+ affinity 
chromatography. The His-tagged wild type recombinant protein retained the affinity to the 
disaccharide, lactose and complex glycoconjugate ligands and induced apoptosis on Jurkat 
cells. The wild type and the mutant his-galectin-1 forms, rHisGal1.48, rHisGal1.71, 
rHisGal1.73 were recognized by the rabbit anti-galectin-1 antibody similarly to the 
recombinant galectin-1 without his-tag. 
 
2. Two mutants, rHisGal1.71 and rHisGal1.73 but not rHisGal1.48 coupled to solid phase 
lactose but not to complex glycoconjugates on the surface of the Jurkat cells. The mutants 
maintaining the lactose binding capacity, induced apoptosis of the Jurkat cells, in contrast to 
the “null-binding” mutant, rHisGal1.48. 
 
3. For analysis of the function of the intracellular galectin-1, the cDNA was stably transfected 
and overexpressed in Jurkat cells. The de novo expressed galectin-1 caused the upregulation 
of TCR expression but did not effect the expression of CD45, CD2, LFA1, MHCI, and CD95. 
 
4. The galectin-1 expressing Jurkat cells had lower proliferation rate, higher amplitude of the 
Ca2+ response upon TCR stimulation or using Ca ionophore, and higher susceptibility to 
galectin-1 induced apoptosis in comparison to galectin-1 non-expressing cells. 
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8.Appendix 
 
Reagents and antibodies 
All restriction and modification enzymes were purchased from MBI Fermentas 
(Vilnius,Lithuania). 
All other reagents if not otherwise indicated were purchased from Sigma-Aldrich Kft. 
(Budapest, Hungary). 
 
Antibodies used: 
1. OKT3 (Ortho, Raritan, USA) recognizes CD3ε chain; 
2. GB3 (produced in our lab(159))-recognizes all isoforms of CD45; 
3. KD3 (produced in our lab(159))-recognizes CD45RA; 
4. TMB6-5 (produced in our laboratory) – recognizes MHC class I; 
5. Anti-CD95 (BectonDickinson) – recognizes CD95; 
6. BT11 (generous gift of Michael Crumpton, ICRF) – recognizes CD2 
7. ITM3 (produced in our laboratory) – recognizes LFA1; 
8. Rabbit anti-galectin-1 antibody (produced in our laboratory) – recognizes human  
galectin-1; 
 
Buffers and Solutions 
 
RPMI cell culture medium: 
1,04% (w/v) RPMI 1640 powder (Gibco BRL) 
0,2% (w/v) NaHCO3 
10 NE/ml penicillin (Biogal) 
0,1 mg/ml streptomycin (EGIS) 
after sterilization 0,63 mg/ml L-glutamine, 5% (v/v) or 10% (v/v) heat inactivated 
foetal calf serum (FCS, Protein GMK, Gödöllő) were added. 
DMEM cell culture medium: 
1,34% (w/v) DMEM powder (Gibco BRL) 
0,37% (w/v) NaHCO3 
10 NE/ml penicillin (Biogal) 
0,1 mg/ml streptomycin (EGIS) 
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after sterilization 0,63 mg/ml L-glutamine, 5% (v/v) or 10% (v/v) heat inactivated 
foetal calf serum (FCS, Protein GMK, Gödöllő) were added. 
Trypan Blue solution for cell counting: 
0,16% (w/v) trypanblue 
0,9% (w/v) NaCl 
 
Antioxidants: 
1 mM sodium pyruvate; 
50 mM a-thioglycerol (a-TG); 
20 nM bathocuproindisulfonic acid disodium salt (BCS). 
 
LB: 
10 g/l tripton 
5 g/l yeast extract (Difco) 
5 g/l NaCl (Merck) 
pH 7,0 
 
Buffers for alpha-lactose gel (EY Laboratories) column purification: 
Lysis buffer: 
50 mM Tris/HCl pH 7.5 
10 mM EDTA 
Washing buffer: 
50 mM Tris/HCl pH 7.5 
Elution buffer 
50 mM Tris/HCl pH 7.5; 
100 mM lactose. 
Buffers for Ni-NTA-agarose column purification: 
Lysis buffer 
50mM NaH2PO4, pH8.0; 
300mM NaCl; 
20mM Imidasole, pH8.0. 
Washing buffer: 
50mM NaH2PO4, pH6.0; 
300mM,NaCl; 
200mM Imidasole, pH6.0; 
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10% Glycerol. 
Elution buffer: 
50mM NaH2PO4, pH6.0; 
300mM NaCl; 
400mM Imidasole, pH6.0; 
10% Glycerol. 
 
PBS, pH 7,4: 
1,8 mM NaH2PO4 
10 mM Na2HPO4 
135 mM NaCl 
3 mM KCl 
Propidium Iodide Stock Solution: 
50 μg/ml propidium iodide, 
0,1% (w/v) sodium citrate. 
Staining buffer for apoptosis assay: 
PBS supplemented with: 
0,1% (v/v) Triton X-100 
0,1% (w/v) Na-citrate 
10 g/ml RNase 
10 g/ml propidium-iodide (Sigma, Fluka) 
Solutions for Ca/phosphate transfection: 
2.5M calcium chloride (CaCl2) 
2X HBS: 
280mM NaCl 
50mM HEPES acid 
1,5mM Na2HPO4 
Titrate to pH 7.05 - 7.12 
Filter sterilize with 0.2 μm membrane 
 
Reducing SDS sample buffer stock: 
125 mM Tris/HCl pH 6,8; 
20% (v/v) glycerine; 
4% (w/v) SDS; 
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2% (v/v) -mercaptoethanol; 
bromfenolblue (Bio-Rad). 
Stacking gel: 
5% (w/v) acrylamide / 0,13% (w/v) bis-acrylamide (Bio-Rad); 
125 mM Tris/HCl pH 6,8; 
0,1% (w/v) SDS; 
0,033% (w/v) ammonium-peroxydisulfate (APS); 
0,07% (v/v) N, N, N, N’- tetrametil-ethylene-diamine (TEMED) (Bio-Rad); 
Running gel: 
7-15% (w/v) acrylamide 0,182-0,39% (w/v) bis-acrylamide (Bio-Rad)  
125 mM Tris/HCl pH 8.8; 
0,1% (w/v) SDS; 
0,033% (w/v) APS; 
0,07% (v/v) TEMED (Bio-Rad). 
Running buffer: 
25 mM Tris/HCl pH 8,3 
194 mM glicin 
0,1% (w/v) SDS 
Coomassie Brilliant Blue G-250 for staining of protein gels: 
0,1% (w/v) Coomassie Brillant Blue G-250; 
50% (v/v) methanol; 
10% (v/v) acetic acid. 
Protein gel destainer: 
10% (v/v) acetic acid 
Transfer buffer: 
25 mM Tris-HCl pH 8,3; 
194 mM glicin; 
20% (v/v) methanol. 
TBST: 
10 mM Tris-HCl pH 7,5; 
150 mM NaCl; 
0,05% (v/v) Tween 20. 
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Abbreviations 
AICD – activation-induced cell death 
AP-1 - activator protein 1 
C2GnT - core 2-beta-1,6-N-acetylglucosaminyltransferase 
GAL1 – galectin-1 gene 
CD -cluster of differentiation 
CIA - collagen-induced arthritis 
GF/C - glass microfibre/C series(1.2µm) 
GM1(Galβ1 3GalNAcβ1 4[Siaα2 3]Galβ1 4Glcβ1-Cer) - receptor for cholera toxin 
Con A – concavalin A 
CRD – carbohydrate recognition domain 
ECL - enhanced chemiluminescence 
EDTA - ethylenediaminetetraacetic acid 
EGTA - ethylnglycol-bis-N, N, N’ ,N’-tetraacetic acid 
ER – endoplasmatic reticulum 
FACS - fluorescent activated cell sorter 
FCS – foetal calf serum 
HRPO - horse-radish peroxidase 
His(H) - histidine 
IFN - interferon 
Ig - immunoglobulin 
IL – interleukin 
Kd – dissociation constant 
LFA – lymphocyte function antigen 
M-phase – phase of mitosis during cell cycle 
MTT - methylthiazoletetrazolium 
NF-AT - nuclear factor of activated T cells 
NFκB - nuclear factor κB 
NTA - nitrilo-triacetic acid 
PAGE - polyacrylamide gel electrophoresis 
PBS - phosphate buffered saline 
PHA - phytohemagglutinin 
PI – propidium iodide 
PI3K - phosphatidylinositol 3-kinase 
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PKC – protein kinase C 
PLC phospholipase C 
PMSF - phenylmethhylsulfonyl fluoride 
Ras – rat sarcoma 
rGal1-1 – recombinant human galectin-1 
rHisGal1 – recombinant human His6 tagged galectin-1 
rHisGal1.48 - recombinant human His6 tagged galectin-1 with amino acid substitution at  
position 48 
rHisGal1.71 - recombinant human His6 tagged galectin-1 with amino acid substitution at  
position 71 
rHisGal1.73 - recombinant human His6 tagged galectin-1 with amino acid substitution at  
position 73 
SDS - sodium dodecyl sulfate 
TBS - tris-buffered saline 
TBST - tris-buffered saline containing Tween20 
TCR – T cell antigen receptor 
WGA – wheat germ agglutinin. 
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11. Summary 
 
The human galectin-1 belongs to the family of N-acetyllactosamine binding lectins. It 
specifically binds to glycoconjugates via its carbohydrate recognition domain (CRD) that is 
highly homologous within the members of the galectin family. The galectin-1 is expressed in 
a wide range of different tissues. Most importantly, immune cells, such as activated T cells 
and macrophages, express the lectin at the site of the immune reactions where galectin-1 acts 
as a strong immunomodulator. The immunomodulatory function of the galectin-1 is attributed 
to its apoptosis inducing capacity on activated T lymphocytes. The role of the carbohydrate 
recognition of galectin-1 in the induction of apoptosis has been disputed for a long time. It is 
also poorly understood whether the de novo expressed intracellular galectin-1 affects the 
cellular functions, including the sensitivity to different apoptotic stimuli of the activated T 
lymphocytes. 
 
Our aim was to study the following main questions:  
1. It has not been clearly defined whether the carbohydrate binding of the galectin-1 is 
essential for the apoptotic function of the protein. The main reason for this is that the 
purification of the non-binding mutants with the classical sugar-matrix affinity 
chromatography encountered difficulties. Therefore our purpose was: 
a) To establish a system that would provide a way to isolate this kind of mutant proteins. 
b) To analyze whether or not these mutants, characterized previously as “sugar non-binding” 
are able to trigger apoptosis of T lymphocytes. 
c) To investigate how are particular amino acid mutation, that is directly couple to 
carbohydrate, affect the galectin-1 induced apoptosis. 
 
2. To obtain a deeper inspite into the intracellular function of the galectin-1 we studied: 
a) How the de novo expressed galectin-1 modulates the T cell functions. 
b) The role of the lectin property of the galectin-1 in its intracellular function. 
 
The results obtained in this work are as follows: 
1. A single mutation in the gal1 gene at the positions E71Q, R73H, resulted in a reduced and 
R48H an abrogated lactose-binding capacity. None of these mutants bound to cell surface 
glycoconjugates. 
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2. The two mutant with retained lactose-binding (rHisGal1.71 and rHisGal1.73) but not the 
“null-mutant”, rHisGal1.48 induced apoptosis in the Jurkat cells. 
3. Presence of intracellular galectin-1 caused  
a) a slower proliferation; b) an elevated TCR expression; c) a higher Ca2+ response 
induced via the TCR or with Ca2+ ionophore; d) an increase in the mitochondrial activity and 
e) a higher sensitivity of the Jurkat cells toward extracellular galectin-1 triggered apoptosis.  
 
The conclusions drawn from this study are: 
1. The results obtained in regard to the extracellular function of galectin-1 with carbohydrate 
non-binding mutants indicate that this quality is only partially required for the induction of 
apoptosis in T cells.  
2. The expression of intracellular galectin-1 results in the upregulation of the cell surface 
TCR, the inducibility of a Ca2+ response with TCR or ionophore stimulation, an increased 
mitochondrial activity and likely as a result an elevated sensitivity of the extracellular 
galectin-1 induced apoptosis. 
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12. Summary in Hungarian 
 
A humán galektin-1 az N-acetillaktózamin kötő lektinek csoportjába tartozik. Szénhidrátkötő 
doménjén (carbohydrate recognition domain, CRD) keresztül specifikusan kapcsolódik a 
különböző glikokonjugátumokhoz. A CRD szakasz nagyfokú homológiát mutat a galektin 
családba tartozó lektinek között. A galektin-1 expresszióját sokféle szövetben kimutatták. Az 
immun rendszer sejtjei, mint például az aktivált T limfociták és a makrofágok, az 
immunreakciók helyén nagy mennyiségben expresszálják, így a galektin-1 erős 
immunmoduláló hatása érvényesülhet. Gyulladáscsökkentő és az autoimmun folyamatokat 
gátló hatása nagy mértékben köszönhető annak, hogy az aktivált T limfociták apoptózisát 
okozza. A szénhidrát felismerő domén apoptózis indukcióban betöltött szerepe régóta a 
vizsgálatok tárgya.  
A de novo expresszált intracelluláris galektin-1 szerepe különböző sejt funkciókra, beleértve 
az aktivált T-limfociták által a különböző apoptotikus szignálokra adott válasz érzékenységét 
azonban kvéssé vizsgálalt kérdés. 
 
 
Célul tűztük ki a következő problémák vizsgálatát: 
1. Még nem eldöntött, hogy szükséges-e a szénhidrátkötő domén az apoptózis indukcióhoz. 
Ennek legfőbb oka, hogy a szénhidrátkötésre képtelen mutáns formák laktozil-agaróz 
oszlopon történő tisztítása nem lehetséges. Ezért: 
A, Olyan rendszer beállítását tűztük ki célul, amely lehetővé teszi a szénhidrát nem-kötő 
mutáns formák tisztítását. 
B, Vizsgálni kívántuk, hogy a “cukor-nemkötő”- mutánsként karakterizált formák indukálnak-
e apoptózist T-limfocitákon. 
C, Meg akartuk határozni, hogy azok az aminosavak, amelyek közvetlenül kapcsolódnak a 
szénhidráthoz, befolyásolják-e a galektin-1 által indukált apoptózist. 
 
 
2. A sejtek által expresszált intracelluláris galektin-1 funkciójának megértéséhez a következő 
kérdésekre kerestük a választ: 
A, Hogyan szabályozza a de novo expresszált galektin-1 a T sejtek funkcióit. 
B, Mi a galektin-1 lektin (szénhidrát kötő) funkciójának intracelluláris szerepe. 
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A munka során elért eredmények a következők: 
1. A galektin-1 gén E71Q és az R73H mutációi csökkent laktózkötő képességet 
eredményeztek, míg az R48H mutáció a laktóz kötés teljes hiányát okozta. Egyik mutáns sem 
kötődött a sejt felszíni cukorkonjugátumokhoz. 
2. A két csökkent laktóz kötést mutató mutáns (71 és a 73) apoptózist indukált Jurkat sejteken, 
míg a “null-mutáns” 48-as forma nem. 
3. A galektin-1 intracelluláris jelenléte csökkent sejtproliferációt, megnövekedett TCR 
expressziót, TCR vagy Ca2+ ionofór által kiváltott, a kontrollhoz képest megnövekedett 
mértékű Ca2+ választ, mitokondrium aktivitás növekedést és az extracelluláris galektin-1 
kezelésre adott megnövekedett apoptotikus választ okozott. 
 
 
A vizsgálatokból levonható következtetések: 
1. A szénhidrát nem kötő mutánsok vizsgálatából kiderült, hogy a szénhidrátkötőképesség 
csak részben szükséges a galektin-1 általi apoptózis indukcióhoz T sejteken. 
2. A galektin-1 intracelluláris expressziója megnövekedett sejtfelszíni TCR expressziót, 
megnövekedett TCR ill. ionofor által stimulált Ca2+ választ, megnövekedett mitokondriális 
aktivitást, valamint az extracelluláris galektin-1 által indukált apoptózissal szembeni 
megnövekedett érzékenységet eredményez. 
 
